SCHEMBL4171297

SCHEMBL4171297

COc1cc(OC)cc(N(S)C(N)=O)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.42
PARP1 P09874 2/20 0.38
PARP10 Q53GL7 2/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
PARP2 Q9UGN5 1/20 0.38
PARP4 Q9UKK3 1/20 0.38
KMT2A Q03164 3/20 0.37
POLB P06746 1/20 0.37
RXRA P19793 1/20 0.37
ALOX5 P09917 1/20 0.36
PLAU P00749 1/20 0.36
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
MEN1 O00255 1/20 0.36
TSHR P16473 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3051601 0.83 RXRA (0.45) ALDH1A1KMT2ARXRAMEN1TSHR
SCHEMBL73373 0.82 PARP1 (0.53) PARP1
SCHEMBL526027 0.81 CA1 (0.52) PARP1PARP10CA1CA2PARP2
SCHEMBL31034446 0.78 ALDH1A1 (0.44) ALDH1A1PARP1PARP10CA1CA2
SCHEMBL5039044 0.78 CYP1A2 (0.47) ALDH1A1CA1CA2PDE4APDE4B
1,3,5-Trimethoxybenzene SCHEMBL28245468 0.76 ALDH1A1 (0.65) ALDH1A1PARP1PARP10CA1CA2
SCHEMBL3981848 0.75 MTNR1A (0.48) ALDH1A1KMT2ATSHRKDM4E
SCHEMBL4929960 0.74 TPMT (0.38) ALDH1A1PARP1PARP10RXRAALOX5
SCHEMBL5038744 0.73 MAPT (0.40) ALDH1A1KMT2AMEN1MAPT
SCHEMBL1617333 0.73 MAPT (0.42) ALDH1A1CA1CA2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents CHEN XIAOLING 2009-12-24 US disclosed
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS IMCLONE SYSTEMS INCORPORATED (US) 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048301-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS TP53, MCL1, VHL ALDH1A1 535/4885PARP1 91/4885PARP10 608/4885
US-20090318438-A1 Heterocyclic compounds and their use as anticancer agents TP53, MCL1, VHL ALDH1A1 535/4885PARP1 91/4885PARP10 608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.